The facility, close to Middlesbrough, UK, was previously used for manufacturing omega-3 products.
“This acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” commented Oscar Groet, CEO of KD Pharma Group.
KD Pharma said it strives to be the leading manufacturer in the rapidly growing omega-3 API market.
“The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids,” added Groet.
The UK site acquisition will enable it to meet market demand for the highest quality APIs in response to new product approvals, label expansions, and supportive clinical research, said the firm.
The company says the site will be brought online this year and operated alongside its other manufacturing sites in Bexbach, Germany; Brattvag, Norway; and Miami, United States.